Study #2023-0883
Stereotactic ablative radiotherapy (SABR) in renal cell carcinoma (RCC): international radiosurgery oncology consortium for kidney (IROCK) prospective registry
MD Anderson Study Status
Enrolling
Treatment Agent
Description
Stereotactic ablative radiotherapy (SABR) in renal cell carcinoma.
Resources and Links
Phone Number: 1-877-MDA-6789
clinicaltrials.gov NCT No: N/A
Information and next steps
Disease:
Kidney
Study phase:
Not applicable
Physician name:
Chad Tang
Department:
Radiation Oncology
For general questions about clinical trials:
1-877-632-6789
Help #EndCancer
Give Now
Your gift will help make a tremendous difference.
Donate Blood
Our patients depend on blood and platelet donations.
Shop MD Anderson
Show your support for our mission through branded merchandise.